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Summary
Chk1 kinase coordinates cell cycle progression and preserves genome integrity. Here, we show that chemical or genetic
ablation of human Chk1 triggered supraphysiological accumulation of the S phase-promoting Cdc25A phosphatase, pre-
vented ionizing radiation (IR)-induced degradation of Cdc25A, and caused radioresistant DNA synthesis (RDS). The basal
turnover of Cdc25A operating in unperturbed S phase required Chk1-dependent phosphorylation of serines 123, 178, 278,
and 292. IR-induced acceleration of Cdc25A proteolysis correlated with increased phosphate incorporation into these
residues generated by a combined action of Chk1 and Chk2 kinases. Finally, phosphorylation of Chk1 by ATM was required
to fully accelerate the IR-induced degradation of Cdc25A. Our results provide evidence that the mammalian S phase
checkpoint functions via amplification of physiologically operating, Chk1-dependent mechanisms.
Introduction eases to cancer (Rotman and Shiloh, 1999; Hartwell and Kastan,
1994).
A growing number of genetic syndromes highly prone to cancer The S phase checkpoint is an evolutionarily conserved signal
share an aberrant cellular response to DNA double-strand transduction pathway responding to IR-induced DSBs by a
breaks (DSB), the most lethal type of DNA damage. When ex- rapid inhibition of origins of DNA replication (Kastan and Lim,
posed to ionizing radiation (IR) or radiomimetic drugs, these 2000). The master (and the most proximal) transducer of the S
cells are unable to slow down the rate of DNA replication and phase checkpoint is ataxia-telangiectasia-mutated protein
undergo the so-called radioresistant DNA synthesis (RDS) (Kas- (ATM), a member of an evolutionarily conserved family of phos-
tan and Lim, 2000; Rotman and Shiloh, 1999). RDS was first phatidyl inositol 3-like kinases (Rotman and Shiloh, 1999). One
reported for cells derived from ataxia-telangiectasia (A-T) pa- critical event downstream of ATM is degradation of the S phase-
tients (Painter and Young, 1980), and later found in Nijmegen- promoting Cdc25A phosphatase (Falck et al., 2001). IR-induced
breakage syndrome (NBS) (Khanna and Jackson, 2001), ataxia- accelerated proteolysis of Cdc25A leads to inhibition of the
telangiectasia-like disorder (A-TLD) (Stewart et al., 1999) and Cdk2 kinase activity, which in turn prevents loading of the Cdc45
Fanconi anemia (FA) (Taniguchi et al., 2002). Moreover, cells origin binding factor on chromatin (Costanzo et al., 2000; Falck
derived from tumors with mutated BRCA1 (Xu et al., 2001) and et al., 2002). Lack of Cdc45 precludes recruitment of DNA poly-
Chk2 (Falck et al., 2001) tumor suppressor, respectively, also merases, thereby blocking initiation of DNA replication from the
undergo RDS when irradiated. It has been proposed that in unfired origins (Takisawa et al., 2000).
ATM propagates (and presumably amplifies) the signalcombination with defects in other cell cycle checkpoints, RDS
may contribute to destabilize the genome and thereby predis- through downstream effector kinases. One such mediator is
Chk2, a Ser/Thr protein kinase, which requires phosphorylationpose individuals suffering the above-mentioned genetic dis-
S I G N I F I C A N C E
Cancer cells commonly possess aberrations in both the cell cycle machinery and the checkpoint pathways activated by DNA
damage. The Cdc25A phosphatase is a cell cycle regulatory protooncogene that is overexpressed in aggressive tumors, and a
target of checkpoint pathways mediated by Chk1 and Chk2 kinases, two tumor suppressors mutated in diverse human malignancies.
Here we report that Chk1 phosphorylates Cdc25A and thereby controls the Cdc25A protein turnover in unperturbed cell cycles. This
mechanism is enhanced jointly by ATM-controlled Chk1 and Chk2 to provide a proper cell cycle-delay response to ionizing radiation.
Our concept helps to elucidate the contributions of Cdc25A, Chk1, and Chk2 deregulation to oncogenesis, and suggests a way to
sensitize cancer cells to radiotherapy.
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by ATM for its activation (Matsuoka et al., 1998). Chk2 directly mechanistic insights into how Chk1 and Chk2 cooperate to
avoid potentially cancer-promoting consequences of unsched-interacts with and phosphorylates Cdc25A in an ATM- and IR-
dependent manner (Falck et al., 2001). However, the complexity uled DNA replication in response to IR.
of Cdc25A phosphorylation and the spectrum of potential ki-
nases involved in this process are not completely understood. Results
Primary embryonic fibroblasts (MEFs) from mice with homozy-
gous disruption of the Chk2 gene did not undergo RDS, although Chk1 is required to control basal turnover and IR-induced
downregulation of Cdc25Aimmortalized cell lines derived from such Chk2-deficient MEFs
did show a delayed initiation and shorter duration of the S phase To elucidate the role of Chk1 in the regulation of Cdc25A, we
inhibited Chk1 in several different ways and assayed the impactcheckpoint (Hirao et al., 2002). These findings indicate that the
absence of Chk2 during embryonic development could trigger on Cdc25A abundance and activity. First, addition of the Chk1
inhibitor UCN-01 (Busby et al., 2000; Graves et al., 2000) for 1some compensatory signaling pathway.
Accelerated proteolysis of Cdc25A was originally discov- hr to human U2-OS cells in the absence of IR caused increased
Cdc25A protein level and activity (Figure 1A, lane 2). In cellsered as a cellular response to ultraviolet light (UV)-induced DNA
damage (Mailand et al., 2000) and hydroxyurea (HU)-triggered grown without any drug, the Cdc25A protein and activity rapidly
declined after 10 Gy IR (Figure 1A, lane 3), yet this responsestalling of replication forks (Molinari et al., 2000). Degradation
of Cdc25A was also observed under physiological conditions was abrogated when UCN-01 was added immediately before
(Figure 1A, lane 4) or after (Supplemental Figure S1 at http://during midblastula transition in Xenopus embryos (Shimuta et
al., 2002). Phosphorylation (and the consequent destruction) of www.cancercell.org/cgi/content/full/3/3/247/DC1) irradiation.
Consistent with the established role of Cdc25A in Cdk2 activa-Cdc25A in all those cases is mediated by a Chk1 Ser/Thr protein
kinase. Chk1 is structurally unrelated to Chk2, and despite other tion, cyclin E/Cdk2 and cyclin A/Cdk2 activities increased after
UCN-01 treatment, similarly to the Cdc25A activity (Figure 1A).indications of their nonoverlapping functions (Hirao et al., 2002;
Liu et al., 2000), there is evidence to suggest that at least in Next, we inhibited Chk1 by a new chemical inhibitor, CEP-3891,
which is distinct from UCN-01 and likely more specific for Chk1some responses to genotoxic stress, Chk1- and Chk2-con-
trolled pathways might converge on shared targets. Most nota- as, for example, it does not inhibit other UCN-01 targets such
as c-Tak1 kinase (Supplemental Figure S2 and Supplementalbly, Chk1 and Chk2 can phosphorylate the same substrates in
vitro, including checkpoint regulators such as p53 (O’Neill et Tables S1 and S2). Analogous to UCN-01, treatment of nonirra-
diated U2-OS cells with CEP-3891 caused a detectable increaseal., 2002; Shieh et al., 2000), Cdc25C (Matsuoka et al., 1998),
and Cdc25A (Falck et al., 2001; Sanchez et al., 1997). in Cdc25A protein level and activity (Figure 1B, lane 3), and
addition of CEP-3891 immediately before IR (Figure 1B, lane 4)It has been speculated that Chk1 might be the factor that
compensates for the lack of Chk2 in the S phase checkpoint diminished the rapid IR-induced downregulation of Cdc25A.
To validate the experiments performed by chemical inhibi-in primary mouse cells (Hirao et al., 2002). Although plausible,
a role of Chk1 in the rapid IR-induced intra-S-phase responses tors, we downregulated Chk1 expression by RNA interference
(RNAi). HeLa cells transfected with Chk1-directed short inhibi-has not been directly demonstrated, and, in general, the specific
function(s) of mammalian Chk1 in DSB-activated checkpoints tory RNA (siRNA) oligonucleotides grossly reduced the Chk1
protein abundance and kinase activity (Figure 1C). Consistentis unclear. Rather than ATM, the major upstream activator of
Chk1 appears to be ATR (ATM- and Rad3-related), another with the effects seen with both chemical inhibitors of Chk1,
Cdc25A protein level and activity increased in siRNA-transfected,member of the PI3 kinase family, associated mainly with non-
DSB types of DNA damage (Abraham, 2001). Apart from the nonirradiated cells (Figure 1C, lane 5), and the IR-induced down-
regulation of Cdc25A was impaired (Figure 1C, lane 6). Thus,uncertainty about the unique versus redundant roles of Chk1
and Chk2 in regulating Cdc25A degradation in response to three independent tools of Chk1 inhibition lead to Cdc25A stabi-
lization in unstressed cells and prevented its efficient degrada-distinct types of genotoxic stress, the observation that Cdc25A
protein is unstable also in undamaged interphase cells (Mailand tion after IR. The specificity of Chk1 inhibition in our assays was
confirmed by the lack of any impact of the Chk1-targeting toolset al., 2000; Molinari et al., 2000) raises yet another conceptually
important question. It is not known whether the damage-induced on Chk2 kinase activity toward Cdc25A (Figure 1D). Collectively,
these data suggest that Chk1 controls both the basal and theenhanced degradation of Cdc25A reflects an amplification of a
mechanism that operates during each physiological S phase or IR-induced accelerated turnover of Cdc25A.
whether it requires activation of a specialized pathway(s) that
are dormant in unstressed cells. Identification and characterization of the Chk1-targeted
phosphorylation sites of Cdc25A in vivoIn an attempt to address these questions, we performed a
detailed analysis of Cdc25A phosphorylation in vitro and in vivo. The above results suggested that Chk1 regulates Cdc25A via
direct phosphorylation. To explore Cdc25A phosphorylation inWe show that Chk1 controls the basal physiological turnover
of Cdc25A through phosphorylation of four serine residues. After vivo, U2-OS cells were transfected with a tetracycline inducible
HA-tagged Cdc25A, an approach used to avoid any deleteriousIR, the activated Chk2 coregulates a subset of these residues
on Cdc25A. Furthermore, the IR-induced acute acceleration of effects of prolonged overexpression of Cdc25A. Cdc25A was
induced for 6 hr, radiolabeled with 32P-ortho-phosphate, immu-Cdc25A proteolysis requires ongoing Chk1 activity, as well as
ATM-mediated phosphorylations of Chk1. The switch between nopurified, and used to generate phosphopeptide maps (Figure
2A). Over 20 phosphopeptides were detectable, and since simi-the basal and the accelerated proteolysis of Cdc25A is deter-
mined by the rate of phosphate turnover on the phosphoaccep- lar patterns were obtained using the much weaker isotope 33P-
ortho-phosphate (data not shown), these results do not seemtor site(s) jointly targeted by Chk1 and Chk2, rather than any de
novo checkpoint-specific phosphorylations. Our results provide to be biased by 32P-induced damage during the labeling period.
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Figure 1. Chk1 controls Cdc25A protein level in
both unstressed and irradiated cells
A: Chk1 inhibition by UCN-01 causes increased
amount of Cdc25A protein and phosphatase
activity, and increased cyclin E/A kinase activi-
ties. Extracts were prepared from U2-OS cells at
1 hr after IR. UCN-01 was added immediately
prior to irradiation. Inhibition of Chk1 was con-
firmed by an in vitro kinase assay with or without
UCN-01. Cdk7 protein levels demonstrate equal
protein input.
B: Chk1 inhibition by CEP-3891 enhances the
Cdc25A protein level and phosphatase activity.
U2-OS cells were treated with CEP-3891, irradi-
ated, and 1 hr later analyzed by Western blot-
ting. Inhibition of Chk1 was confirmed by an in
vitro kinase assay with or without CEP-3891.
C: Chk1 inhibition by siRNA causes increased
amount of Cdc25A protein and phosphatase
activity. HeLa cells were irradiated at 34 hr after
transfection with control or Chk1 siRNA and ex-
tracts were prepared 1 hr later. Reduced expres-
sion of Chk1 protein was confirmed by Western
blotting and in vitro kinase assay.
D: Chk2 kinase is not inhibited by Chk1 inhibition.
In vitro kinase assays for Chk1 and Chk2 are
shown in the absence and presence of Chk1
inhibitors. Chk2 autophosphorylation is also
shown. Extracts from HeLa cells were prepared
at 1 hr after irradiation of cells pretreated with
Chk1 inhibitors for 15 min (UCN-01 and CEP-3891)
or 34 hr (siRNA-transfection).
When 33P-ortho-phosphate was used to label the cells, IR expo- confirmed by phosphopeptide mapping of GST-Cdc25A where
sure (15 Gy) did not lead to any major change of the phospho- S123 was altered to alanine (data not shown).
peptide pattern, suggesting that IR does not induce de novo We next phosphorylated GST-Cdc25A in vitro with recombi-
phosphorylations on Cdc25A (negative data not shown). Impor- nant Chk2 (Figure 3B). Chk2 phosphorylated Cdc25A in a man-
tantly, inhibition of Chk1 by addition of UCN-01 (Figure 2B) or ner partly overlapping with Chk1. However, the site identified
CEP3891 (Supplemental Figure S3 at http://www.cancercell. as S278 was almost undetectable upon phosphorylation with
org/cgi/content/full/3/3/247/DC1) led to a clear reduction in Chk2, while the spots corresponding to phosphorylation on
phosphorylation of at least 4 residues on Cdc25A. This shows S123, S178, and S292 were clearly detectable. The similarity
that Chk1 phosphorylates Cdc25A in vivo on residues that might of the Chk1 and Chk2 phosphorylation patterns was confirmed
be critical for its stability. by creating a map where we combined GST-Cdc25A that had
The precise identity of the individual phosphopeptides was been separately phosphorylated by Chk1 and Chk2. Indeed,
determined by phosphoamino acid analysis and cycle sequenc- the phosphopeptides corresponding to S123, S178, and S292
ing of the tryptic phosphopeptides from in vivo labeled Cdc25A, clearly comigrated (Figure 3C). Compared to these 3 phospho-
combined with site-directed mutagenesis. We identified the four peptides, the S278 spot was weaker in the combined map than
Chk1-targeted phosphorylated sites as serines 123, 178, 278, in the Chk1-exclusive map, indicating that this peptide is almost
and 292 (Figure 2C and Supplemental Figure S4). The spot exclusively phosphorylated by Chk1 (Figure 3C). The fact that
containing S178 was not completely eliminated upon alanine Chk2 could only phosphorylate a subset of the sites suggests
substitution of S178 due to comigration of two phosphopeptides that the roles of Chk1 and Chk2 in regulation of Cdc25A may
(data not shown). To rule out overexpression-associated ad-
not be simply redundant.
verse effects, phosphopeptide maps of endogenous Cdc25A
were determined, and the Chk1-regulated sites confirmed (Fig-
Phosphorylation of serines 123, 178, 278, and 292ure 2D). Together, these data suggested that Chk1 phosphory-
regulates both basal and IR-inducedlates Cdc25A on four residues.
accelerated proteolysis of Cdc25A
We next tested phosphorylation-site mutants of Cdc25A forChk2 phosphorylates a subset of the Chk1-targeted
their ability to be downregulated in the absence or presence ofsites of Cdc25A
IR. Consistent with our previous results (Falck et al., 2001), theTo confirm that the in vivo-identified sites of Cdc25A could be
turnover of wild-type Cdc25A was accelerated in cells exposeddirectly phosphorylated by Chk1, a GST-Cdc25A fusion protein
to IR (Figure 4A, upper panel). We then generated a Cdc25Awas phosphorylated in vitro with recombinant Chk1. Among the
mutant (S123A, S178A, S278A, and S292A) that lacks all phos-sites, which were phosphorylated, we could identify S123, S178,
pho-sites identified in this study. This quadruple mutant wasS278, and S292 (Figure 3A). Although phosphorylated S123
often appeared as a smear, rather than a spot, its identity was significantly more stable than the wild-type Cdc25A regardless
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Figure 2. Chk1 phosphorylates Cdc25A on S123,
S178, S278, and S292 in vivo
A: Phosphopeptide map of in vivo [32P]-labeled
HA-tagged Cdc25A from U2-OS cells. Expression
of HA-Cdc25A was induced by tetracycline
removal for 6 hr prior to the labeling with [32P]-
orthophosphate (0.5 mCi/ml) for 2 hr. The
immunopurified HA-Cdc25A was processed for
phosphopeptide mapping.
B: Addition of UCN-01 reduces the phosphoryla-
tion of Cdc25A on specific residues in vivo. U2-
OS cells were treated with UCN-01 during the
[32P]-labeling period and analyzed as in A.
C: S123, S178, S278, and S292 are major UCN-01-
sensitive phosphorylation sites of Cdc25A. Phos-
phopeptide mapping was performed as in A
with an inducible HA-Cdc25A construct harbor-
ing alanine substitutions of S123, S178, S278, and
S292.
D: Phosphopeptide mapping of endogenous
Cdc25A from U2-OS cells.
Parental U2-OS cells were labeled and subjected
to phosphopeptide mapping. Asterisks indicate
the sample application points. Arrows and num-
bers indicate the following phosphopeptides: (1)
S123, (2) S178, (3) S292, and (4) S278.
of IR exposure in both cycloheximide (Figure 4A, lower panel) cause in our assays, it was the only single phosphorylation site
whose mutation clearly affected the stability of Cdc25A. Theand 35S-methionine-based (Figure 4B) pulse-chase assays.
We and others previously showed that mutation of serine antibody recognized Cdc25A prephosphorylated in vitro with
either Chk1 or Chk2 (Figure 5A), and its specificity was docu-123 alone was sufficient to impair the IR-induced Cdc25A degra-
dation (Falck et al., 2001; Donzelli et al., 2002). We therefore mented by the lack of reactivity with similarly prephosphorylated
Cdc25A-S123A. Western blotting with anti-pS123 on lysatescompared the stability of a Cdc25A-S123A mutant with the
quadruple mutant or various combinations of mutations (Figure from IR-exposed versus untreated cells showed that S123 was
already phosphorylated in undamaged cells (data not shown).4C and data not shown). These experiments confirmed that
S123 is indeed a prominent residue involved in regulating the This result is consistent with our phosphopeptide mapping data,
which did not identify any de novo DNA damage-induced phos-Cdc25A protein turnover, as this was the only site that affected
the Cdc25A half-life when mutated alone, and prevented the pho-sites on Cdc25A.
We then assayed the kinetics of Cdc25A phosphorylationIR-induced degradation (Figure 4C and data not shown). Adding
two more mutations to S123 in a triple mutant had no additional in cell extracts, using the pS123 antibody. In extracts from
undamaged cells, S123 was phosphorylated after 5 min of incu-effect. However, the quadruple mutant was more stable than
Cdc25A-S123A both with and without irradiation (Figure 4C). bation, and after 20 min, Cdc25A appeared in shifted forms
(Figure 5B). In contrast, after IR exposure, the kinetics of S123Thus, concomitant phosphorylation of the four serines 123, 178,
278, and 292 is required for optimal regulation of Cdc25A sta- phosphorylation were faster and Cdc25A shifted more rapidly
to slower migrating forms. Importantly, the chemical inhibitionbility.
of Chk1 or Chk2 resulted in a delay in the IR-induced S123
phosphorylation, and this effect was consistently augmentedThe rate of phosphate exchange on the Chk1/Chk2-
targeted S123 is modulated by IR when both inhibitors were combined (Figure 5C). These data
indicate that after IR-induced DNA damage, both Chk1 andTo study how Chk1- and Chk2-mediated phosphorylations reg-
ulate the turnover of Cdc25A, we used an antibody against Chk2 participate in phosphorylating Cdc25A on a residue critical
for its stability. To validate the latter conclusion in vivo, wephosphoserine123 (anti-pS123). This residue was chosen be-
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Figure 4. Cdc25A protein stability is dependent on phosphorylation of S123,
S178, S278 and S292 regardless of DNA damage
A: Increased stability of the Cdc25A-4xA mutant in U2-OS cells. At sixteen
hr after transfection with wild-type HA-Cdc25A or the Cdc25A-4xA mutant,
cells were irradiated with 10 Gy as indicated, and cycloheximide was
added immediately to block new protein synthesis. At the indicated time
points, whole-cell lysates were immunoblotted with the anti-HA antibody.
Asterisks indicate a crossreacting protein shown here as a loading marker,
and pX indicates cells transfected with empty vector.
B: Increased stability of the Cdc25A-4xA mutant in a [35S]-methionine pulse-
chase. U2-OS cells were transfected with wild-type HA-Cdc25A or HA-
Cdc25A-4xA expression plasmids. Sixteen hr later, the cells were pulsed with
[35S]-methionine (0.1 mCi/ml) for 30 min and harvested at the indicated
times. HA-Cdc25A was immunoprecipitated, separated by SDS-PAGE, and
analyzed by autoradiography. An asterisk indicates a crossreacting protein.
C: Quantitation of data from cycloheximide pulse-chase experiments with
wild-type or the indicated mutants of HA-Cdc25A performed as in A. The
plotted values show the levels of remaining HA-Cdc25A proteins measured
between 30 min and 1 hr after IR and addition of cycloheximide, relative
to the levels in lysates from untreated cells. The results shown are an average
of 3–4 independent experiments.
selectively targeted Chk1 and Chk2, respectively, in live cellsFigure 3. Chk1 and Chk2 share partly overlapping phosphorylation sites on
Cdc25A in vitro by RNAi. Indeed, the genetic downregulation of either Chk1 or
A: Phosphopeptide map of GST-Cdc25A phosphorylated in vitro with re- Chk2 also leads to a decrease of IR-induced phosphorylation
combinant Chk1 shows phosphorylation of S123, S178, S278, and S292. of Cdc25A on S123 (Figure 5D). Together, these data suggest
B: Recombinant Chk2 phosphorylates S123, S178, and S292 on GST-Cdc25A that the turnover of Cdc25A is regulated by a two-step mecha-
in vitro.
nism. First, in undamaged cells, Chk1 alone determines theC: Comigration of S123, S178, and S292 phosphopeptides after mixing equal
basal degradation rate of Cdc25A by continuous phosphoryla-amounts of GST-Cdc25A separately phosphorylated by Chk1 and Chk2,
respectively. Asterisks indicate the sample application points. Plain arrows tion of S123 and three other sites identified in this study. Second,
point to the S123, S178, and S292 phosphopeptides shared by Chk1 and after IR exposure, the rate of phosphate incorporation into at
Chk2; dashed arrow indicates S278, specific for Chk1.
least a subset of these residues increases due to a combination
of the ongoing activities of Chk1- and IR-induced Chk2 that
jointly promote the accelerated turnover of Cdc25A.
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Figure 5. Accelerated rate of phosphorylation of
S123 after IR
A: An in vitro kinase assay using recombinant
Chk1 and Chk2 to phosphorylate wild-type GST-
Cdc25A or GST-Cdc25A S123A was followed by
blotting with the phospho S123 antibody (pS123)
to confirm its specificity for S123-phosphorylated
Cdc25A.
B: The kinetics of phosphorylation on S123 were
assayed using extracts prepared from nonirradi-
ated and irradiated U2-OS cells (10 Gy, 1 hr). In
vitro kinase assays were performed using GST-
Cdc25A as a substrate for the indicated times,
followed by Western blotting with the pS123-
phosphospecific antibody.
C: The kinetics of S123 phosphorylation were as-
sayed as in B and evaluated 10 min after initiation
of the kinase reaction. The reactions were sup-
plemented either by DMSO (control reaction) or
with Chk1 inhibitor (CEP-3891), Chk2 inhibitor
(CEP-6367), or both inhibitors combined, respec-
tively (see further characterization of the CEP
drugs in Supplemental Figure S1 and Supplemen-
tal Tables S1 and S2 at http://www.cancercell.
org/cgi/content/full/3/3/247/DC1).
D: Phosphorylation on S123 in vivo requires Chk1
and Chk2. U2OS cells conditionally expressing
HA-Cdc25A were either nontransfected (left two
lanes) or transfected with control, Chk1, or Chk2
siRNA (right 3 lanes). At 30 hr after transfection,
expression of HA-Cdc25A was induced by re-
moval of tetracyclin for 4 hr, followed by irradia-
tion and incubation for 1 hr in the presence of
the proteasome inhibitor MG132 to prevent elimi-
nation of the phosphorylated unstable Cdc25A
protein. Immunoprecipitations using an antibody
to the HA-tag followed by Western blotting with
the pS123 and HA antibodies are shown. Western
blotting of Chk1 and Chk2 demonstrate efficient
downregulation of both proteins by the siRNA
treatments.
Chk1 is required to prevent RDS in cells exposed to IR 6A, middle panel), consistent with the previously identified role
of Chk2 in Cdc25A degradation after IR (Falck et al., 2001).Since inhibition of Chk1 abrogates IR-induced downregulation
of Cdc25A, we asked whether inhibition of Chk1 would affect Combination of Chk1 and Chk2 siRNA did not lead to further
increase in the extent of RDS achieved by single siRNA treat-the S phase checkpoint and cause RDS. Indeed, addition of
the Chk1 inhibitors UCN-01 or CEP-3891 prior to irradiation ments (data not shown). This may indicate that in the absence
of Chk1 (which would lead to stabilization of Cdc25A evenpartly rescued the inhibition of DNA synthesis after IR (Figure
6A, left panel). Consistently, HeLa cells transfected with Chk1 without IR), Chk2 alone is insufficient to stimulate the S phase
checkpoint. In any case, the siRNA data do support our conclu-siRNA showed less inhibition of DNA synthesis in response to IR
than cells treated with control siRNA (Figure 6A, middle panel). sion that Chk1 is an integral component of the rapid IR-induced
S phase checkpoint.Treatment with Chk2-specific siRNA also caused RDS (Figure
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Figure 6. Chk1 is required for the rapid ATM-dependent S phase checkpoint after IR
A: Inhibition of Chk1 abrogates IR-induced inhibition of DNA synthesis. U2-OS cells treated with Chk1 inhibitors UCN-01 or CEP-3891 (left panel), or
HeLa cells transfected with Chk1 or Chk2 siRNA (middle panel), show reduced downregulation of DNA synthesis at 1 hr after IR. No significant effect is
seen by addition of UCN-01 or CEP-3891 to AT fibroblasts (right panel). DNA synthesis relative to nonirradiated cells is shown for each treatment,
respectively.
B: Basal level of Cdc25A is increased in AT-cells after Chk1 inhibition. ATM-deficient GM9607B cells were treated with UCN-01 and exposed to 10 Gy of
IR as indicated. One hr later, the cell lysates were analyzed by Western blotting for the levels of endogenous Cdc25A and Cdk7 (loading marker).
C: Phosphorylation of Chk1 after IR is ATM-dependent and correlates with Cdc25A degradation. Western blots with antibodies specific to Chk1
phosphorylated at serine 317 and Cdc25A are shown for U2-OS cells and AT cells (AT22IJE-T) transfected with control vector or recombinant ATM.
Extracts were prepared at 1 hr after IR. Mcm7 protein is a loading marker.
D: IR-induced ATM directly phosphorylates Chk1. ATM was immunoprecipitated from extracts prepared from 293 cells (left panel) or AT or ATM-
reconstituted AT cells (right panel) at 1 hr after IR. Where indicated, 5 M of the ATM-inhibiting drug Wortmannin was added to show the specificity of
the kinase reaction.
E: ATM phosphorylation of Chk1 is required for efficient IR-induced downregulation of Cdc25A. HeLa cells were transfected with expression plasmids
containing no insert (pX), Flag-Chk1, or Flag-Chk1AA (S317A, S345A). Each reaction was supplied with an expression plasmid for CD20 transfection
marker. Subsequently, cells were transfected with Chk1 siRNA to deplete endogenous Chk1. After additional 30 hr, the cells were irradiated with 10 Gy
for 1 hr, harvested, sorted via CD20-coated magnetic beads, and processed for Western blotting. The assay was reproduced three times with consistent
results.
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ATM directly targets Chk1 to regulate the IR-induced onic lethality (Liu et al., 2000; Takai et al., 2000). This indicates
S phase checkpoint that in metazoans, Chk1 controls essential cell cycle events
ATM-deficient (AT) cells are defective in radiation-induced S irrespective of DNA damage and/or forced replicative stress.
phase checkpoint and display RDS (Painter and Young, 1980). However, specific molecular mechanisms that would mediate
To directly assess the relationship between ATM and Chk1 in the dramatic loss of viability of mammalian cells lacking Chk1
regulating the S phase checkpoint, we examined the effects of have not been characterized. Our results together with a recent
Chk1 inhibition in AT cells. No significant effects were seen on report by Piwnica-Worms and colleagues (Zhao et al., 2002)
DNA synthesis after IR by addition of UCN-01 or CEP-3891 to begin to shed light on this important issue by showing that
AT fibroblasts (Figure 6A, right panel). Consistent with the RDS transient downregulation of Chk1 by inhibitory drugs or RNAi
phenotype, Cdc25A is not degraded efficiently in AT cells after was sufficient to elevate endogenous Cdc25A to supraphysio-
IR (Falck et al., 2001 and Figure 6B). However, addition of logical levels. Overexpression of Cdc25A has dramatic conse-
UCN-01 caused increased Cdc25A protein levels in unstressed quences for cell cycle progression, including unscheduled DNA
A-T cells (Figure 6B, lanes 3 and 4). These data indicate that replication and cell death (Molinari et al., 2000; Vigo et al., 1999).
while Chk1-mediated control over the basal turnover of Cdc25A In addition, excessive accumulation of Cdc25A was found in
is ATM-independent, the accelerated destruction of Cdc25A diverse human malignancies (Cangi et al., 2000; Wu et al., 1998),
after IR may depend on a functional link between ATM and raising a possibility that it can contribute to genetic instability
Chk1. Whether ATM and Chk1 operate along one linear pathway (Galaktionov et al., 1995). Finally, unscheduled expression of
has been tested in the following experiments. cyclin E, the prime target of Cdc25A linked to origin firing
In response to UV light Chk1 kinase activity increases upon (Blomberg and Hoffmann, 1999), was shown to induce gross
phosphorylation on serines 317 and 345 likely mediated by the chromosomal aberrations (Spruck et al., 1999). Based on these
upstream kinase ATR (Guo et al., 2000; Liu et al., 2000; Zhao findings, our present results, and the mounting evidence that
and Piwnica-Worms, 2001). The IR-induced effects on Chk1 Chk1 itself is subverted by mutations in diverse human malig-
are less clear. Using the available phosphospecific antibodies nancies (Bertoni et al., 1999; Menoyo et al., 2001; Vassileva et
and different cell types, we observed that Chk1 was phosphory- al., 2002), we propose that one way mammalian Chk1 protects
lated on S317 and S345 rapidly after IR in a dose-dependent genome integrity may be through counterbalancing the Cdc25A
manner (Figure 6C and data not shown). To test whether IR- synthesis during physiological S phase by promoting its rapid
induced phosphorylation of Chk1 is ATM-dependent, we used turnover, thereby keeping the proreplicative activity of cyclin
AT cells transfected with control vector or stably reconstituted E/Cdk2 within the physiological borders. Consistently, we could
with ATM (Ziv et al., 1997). Strikingly, the control AT cells showed clearly show that cyclin E/Cdk2 kinase activity was upregulated
impaired phosphorylation of Chk1 on S317 after IR, and recon- when Cdc25A was stabilized through Chk1 inhibition (see
stitution with ATM rescued the IR-induced phosphorylation on Figure 1).
S317 (Figure 6C) and S345 (data not shown). As expected, this Since Cdc25A accumulates at the G1/S transition, the model
was accompanied by a restoration of Cdc25A degradation in of a critical role of Chk1 in preventing overaccumulation of
the reconstituted cells after irradiation (Figure 6C). Consistently, Cdc25A in an unperturbed cell cycle predicts that Chk1 is peri-
endogenous ATM immunoprecipitated from 293 cells (Figure odically activated in every S phase. While the majority of studies
6D, left panel) and overexpressed ATM immunopurified from refer to Chk1 as a DNA damage- and/or replication stress-
ATM-reconstituted A-T cells (Figure 6D, right panel) efficiently inducible kinase, a recent report indeed provided evidence for
phosphorylated recombinant Chk1. This phosphorylation in- a close correlation of Chk1 accumulation and increase of its
cluded S317 and S345 (Supplemental Figure S5 at http://
kinase activity without any external DNA stress (Kaneko et al.,
www.cancercell.org/cgi/content/full/3/3/247/DC1 and data not
1999). Our data showing that both chemical and genetic inhibi-
shown). Finally, we tested the relevance of the ATM-mediated
tion of Chk1 decreased the Chk1 kinase activity in nonirradiatedphosphorylation of Chk1 by reconstitution of Chk1 expression
cells (see Figure 1) support such a scenario. We suggest thatin cells deprived of endogenous Chk1 by RNAi. Remarkably,
following its E2F-mediated induction at the G1/S transition (Got-while the wild-type Chk1 efficiently rescued the IR-induced ac-
tifredi et al., 2001; Ren et al., 2002), Chk1 becomes activecelerated turnover of Cdc25A in cells deprived of endogenous
irrespective of DNA damage, possibly by signals transmittedChk1, the Chk1 allele where both S317 and S345 were substi-
from the generation and/or processing of the physiological repli-tuted to alanines was reproducibly less efficient (Figure 6E). This
cation structures. Interestingly, Cdc25A expression is also tran-occurred despite the associated kinase activities of wild-type
scriptionally regulated by E2F (Vigo et al., 1999), indicating thatand mutant Chk1 were similar (data not shown). Collectively,
the complex E2F-regulated S phase-promoting program in-these data suggest that in addition to its role in maintaining the
cludes coordinated induction of a powerful inducer of DNAphysiological turnover of Cdc25A, Chk1 actively contributes to
replication (Cdc25A) with an immediate means (Chk1) to limita full-scale destruction of Cdc25A after exposure to IR, and
this activity, thereby preventing excessive and unscheduled fir-that the latter (but not the former) Chk1 function operates in an
ing of replication origins (Figure 7A).ATM-dependent manner.
Requirement of Chk1 for the IR-induced acceleratedDiscussion
proteolysis of Cdc25A
We could demonstrate that Chk1 is required for IR-inducedRegulation of the basal turnover of Cdc25A: A novel
downregulation of Cdc25A and that ablation of Chk1 functionfunction of Chk1 in cell cycle coordination and
leads to RDS. While this paper was under review, similar obser-maintenance of genome integrity
vations have been reported (Zhao et al., 2002). One way thatA homozygous disruption of Chk1 in mice causes severe check-
point defects in ES cells and results in peri-implantation embry- Chk1 participates in the IR-induced S phase checkpoint may
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help protect this vital cellular factor (in unstressed cells, Chk1
is an unstable protein [Lukas et al., 2001]), or secure and/or
enhance the ongoing access of Chk1 to Cdc25A by recruiting
essential cofactor, such as the recently identified claspin (Kuma-
gai and Dunphy, 2000).
Primary MEFs isolated from mice with a homozygously de-
leted Chk2 gene did not undergo RDS, and it has been reasoned
that Chk1 may compensate for Chk2 in phosphorylation of
Cdc25A (Hirao et al., 2002). Our results provide direct mechanis-
tic evidence that this indeed might be the case, since Chk1
is an essential ATM-regulated component of the IR-induced
signaling to accelerate proteolysis of Cdc25A. On the other
hand, in response to IR, the ATM-dependent phosphorylations
of Chk1 are less pronounced compared to the entirely ATR-
dependent checkpoint responses such as stalled replication
forks and/or the UV-type of DNA damage (Liu et al., 2000; Zhao
and Piwnica-Worms, 2001; and our unpublished data). Thus,
while ATR-mediated checkpoint responses appear to depend
solely on Chk1 to switch the Cdc25A proteolysis to the acceler-
Figure 7. Model for Chk1-mediated regulation of Cdc25A and the S phase ated mode, the IR-induced DNA damage in somatic cells re-
checkpoint quires a cooperative action of other ATM-induced factors such
A: Chk1 controls Cdc25A in the absence of IR. Both Chk1 and Cdc25A are as Chk2 (Figure 7B), previously identified in our laboratory as
positively regulated by the E2F transcription factor when cells enter S phase. one mediator of the timely Cdc25A degradation in response to
Chk1 promotes basal Cdc25A protein turnover by direct phosphorylations
IR (Falck et al., 2001). This “cooperative” model has been furtheron multiple Cdc25A residues (S123, S178, S278, and S292). Cdc25A turnover
strengthened by several new observations in our present study.buffers the Cdc25A phosphatase activity, and thereby its capability to
activate cyclin E/A-cdk2 complexes that regulate S phase entry and pro- First, the selective siRNA downregulation of Chk1 and Chk2,
gression, respectively. respectively, impaired the IR-induced Cdc25A phosphorylation.
B: Chk1 is required for radiation-induced downregulation of Cdc25A. After Second, the same genetic ablation of either kinase producedIR, Cdc25A protein turnover accelerates due to an increased phosphoryla-
a RDS phenotype. Third, the concomitant chemical inhibitiontion on multiple Cdc25A residues that overlap with those constitutively phos-
phorylated by Chk1 in the absence of IR (see A). The increased phosphoryla- of both kinases in extracts from irradiated cells was required
tion of S123, S178, S278, and S292 is achieved by a cooperative action of for a more complete inhibition of the ability of these lysates
ATM-regulated Chk1 and Chk2 kinases. This results in a rapid IR-induced to phosphorylate Cdc25A in vitro (see Figures 5 and 6). The
degradation of Cdc25A, which ultimately leads to inhibition of Cdk2 and
proposed cooperative action of ATM-activated Chk2 and ATM-suppression of initiation of DNA replication.
modified Chk1 might be instrumental to rapidly reach and main-
tain the threshold of the IR-induced cell defense mechanism
that would be sufficiently high to prevent unscheduled origin
firing and other events potentially priming for acute geneticagain relate to its role in controlling the basal turnover of
instability.Cdc25A. As discussed above, the Cdc25A protein is unstable
in normal S phase due to ongoing proteolysis, which is con-
Amplification of basic events associated with DNAtrolled by Chk1 via direct phosphorylation of at least 4 residues.
replication: An effective means to avoid RDSWe propose that such Chk1-mediated basal control of Cdc25A
without irreversible disruption of cellturnover is a necessary prerequisite to accommodate any IR-
cycle progressioninduced signals to accelerate the proteolysis of Cdc25A. Such
Provided the extent of DNA damage is not beyond repair, thea scenario is consistent with our observation that IR exposure
main purpose of cell cycle checkpoints appears to be protectingdid not involve new phosphorylation sites, but rather increased
the genomic integrity and resumption of cell cycle progression.the rate of phosphorylation on the same residue of Cdc25A that
Hence, it would be dangerous, especially if the intra-S-phasewas already phosphorylated by Chk1 in nonirradiated cells (see
checkpoint included powerful but irreversible means to arrestFigure 5).
the cell cycle such as complete destruction of cell cycle regula-Furthermore, we showed that exposure to IR induced ATM-
tors that mark the main unidirectional cell cycle decisions. Itdependent posttranslational modifications of Chk1, including
rather seems that a fine modulation of the ongoing processes,phosphorylation of serines 317 and 345. Together with the ability
such as the dynamics of Cdc25A phosphorylation and proteoly-of immunopurified ATM to phosphorylate Chk1 and the fact that
sis uncovered here, might be the desirable means to slow downmutation of serines 317 and 345 impaired the ability of Chk1
the pace of DNA replication and gain time for a productive repairto promote the IR-induced degradation of Cdc25A, these results
of the lesion.strongly suggest that regulation of the IR-induced S phase
We showed that Chk1 is required for at least one essentialcheckpoint relies on the direct ATM-Chk1 functional interplay.
event (regulation of basal turnover of Cdc25A) accompanyingSuch posttranslational modifications of Chk1 might reflect
every physiological S phase. Regarding the IR-induced S phaseimportant processes required for optimal performance of the
checkpoint, we propose that the ATM signaling to Cdc25A mayChk1 kinase (although they may not necessarily alter the Chk1
not need to initiate damage-specific pathways, but ratherkinase activity to a great extent). Translated specifically to the
Chk1-Cdc25A interplay, IR-induced Chk1 modifications may modulate the kinetics of the existing, Chk1-controlled S phase
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at 1 hr after irradiation. At 20 min after addition of [3H]Thymidine, the cellsprocesses. In such a model, ATM-downstream (and strictly
were fixed in 70% methanol, washed in PBS, and radioactivity was measureddamage-inducible) events including IR-induced modification of
in a liquid scintillation counter. The ratios of [3H]/ [14C] were calculated andChk1 itself (this study) and activation of Chk2 (Falck et al., 2001)
DNA synthesis after irradiation was expressed as a percentage of unirradi-
would act as modifiers, nonessential to support the imminent ated values. This was done to compensate for the differential impact of the
requirement for cell survival but important especially under con- siRNA on basal DNA replication in unirradiated cells (Chk2-directed siRNA
ditions when cells encounter increasing demand to cope with inhibited the basal rate of DNA synthesis to a larger extent than Chk1 or
control siRNA, data not shown).stress and more vigorous replication activity. Active involvement
of Chk1 in the intra-S-phase cell cycle response to IR-induced
Cycloheximide and [35S]-methionine pulse-chasegenotoxic stress, uncovered in this study, is consistent with
Cells were transfected by the calcium-phosphate method for 12 hr. After
candidacy of Chk1 for a tumor suppressor, a notion supported an additional 7 hr, a cycloheximide chase was performed as described
by mutations of Chk1 detected in diverse human malignancies previously (Falck et al., 2001). For [35S]-methionine pulse-chase, cells were
(Bertoni et al., 1999; Menoyo et al., 2001; Vassileva et al., 2002). washed 3 times with methionine-free DMEM at 7 hr after transfection, fol-
lowed by labeling for 0.5 hr with 100 Ci/mL [35S]-methionine (SJQ 0047;
Amersham). Labeling was done in methionine-free DMEM with 10% dialyzedExperimental procedures
serum. Cell lysates were prepared at the indicated time points and processed
for immunoprecipitation.Cell lines and siRNA treatment
Human U2-OS osteosarcoma, 293 kidney epithelial, and HeLa cervical carci-
noma cell lines, U2-OS derivative conditionally expressing HA-Cdc25A (Mai- Orthophosphate labeling and two-dimensional electrophoresis
Cells were labeled for 2 hr in phosphate-free DMEM with 20 mM Hepes (pHland et al., 2000), and AT fibroblasts GM09607 (Coriell Cell Repositories)
7.2), 10% dialyzed serum, and 0.5 mCi/mL [32P]orthophosphate (PBS43;were grown in DMEM medium with 10% fetal bovine serum. Human AT
Amersham). In some experiments, the proteasome inhibitor MG132 (5 M)fibroblasts AT22IJE stably transfected with YZ5 ATM cDNA (Ziv et al., 1997)
was added. Cells were lysed with RIPA-buffer (Harlow and Lane, 1988)were grown in the presence of 100 g/ml hygromycin.
and processed for immunoprecipitation. Two-dimensional phosphopeptideFor siRNA-mediated ablation of Chk1, HeLa cells were transfected with
mapping and phosphoamino acid analysis were performed as describedthe following oligonucleotide sequences: 5-UCGUGAGCGUUUGUUGAA
(Boyle et al., 1991). Tryptic phosphopeptides were separated on thin-layerCdTdT-3 (Chk1 siRNA) and 5-GAAGCAGUCGCAGUGAAGAdTdT-3 (con-
cellulose plates using a Hunter Thin Layer Electrophoresis System (HTLE-trol siRNA), by OligofectAMINETM Reagent (Invitrogen). The control siRNA
7000; 2000 V for 25 min), followed by chromatography in the second dimen-contains a nonfunctional Chk1 target sequence that is unable to downregu-
sion (isobuturic acid buffer).late Chk1. Chk2 siRNA were directed against the sequence 5-AAGAACCU
GAGGACCAAGAACdTdT-3. Experiments with siRNA-transfected HeLa
Elution of peptides for Edman degradationcells were performed at 30–35 hr after transfection. Reconstitution of Chk1
Eluted phosphopeptides were coupled to Sequelon-AA membrane by useexpression in siRNA treated HeLa cells was done by mutating 4 residues in
of carbodiimide coupling, as described by the manufacturer. Edman degra-the siRNA target sequence of Flag-tagged Chk1 (TTGTTG was changed to
dation was performed using an Applied Biosystems gas phase sequencerCTCCTC) that changed the nucleotide but not the amino acid sequence of
(Model 477A) as described (Blume-Jensen et al., 1995).Chk1. Cells were first cotransfected with expression plasmids for Chk1 and
the CD20 transfection marker by the calcium-phosphate method, followed
by siRNA transfection. 30 hr after siRNA treatment, cells were sorted with Acknowledgments
anti-CD20 magnetic beads and lysed (Sørensen et al., 2001).
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